Atıf İçin Kopyala
ÇAKIRCA M., KARATOPRAK C., ZORLU M., KISKAÇ M., Kanat M., Cikrikcioglu M. A., ...Daha Fazla
DRUG DESIGN DEVELOPMENT AND THERAPY, cilt.8, ss.239-243, 2014 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
8
-
Basım Tarihi:
2014
-
Doi Numarası:
10.2147/dddt.s52545
-
Dergi Adı:
DRUG DESIGN DEVELOPMENT AND THERAPY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.239-243
-
Anahtar Kelimeler:
asymmetric dimethylarginine (ADMA), dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, type 2 diabetes mellitus, GLUCAGON-LIKE PEPTIDE-1, MYOCARDIAL-INFARCTION, HEART-FAILURE, DYSFUNCTION, INHIBITION, RATS
-
Dokuz Eylül Üniversitesi Adresli:
Evet
Özet
Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.